A study led by researchers at the American Cancer Society showed Medicaid expansion under the Affordable Care Act was associated with an increase in two-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people living in rural areas.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult cancer survivors of acute lymphoblastic leukemia and acute myeloid leukemia have reduced long-term survival rates compared to their peers without cancer.
Patients with head and neck cancer undergoing radiation therapy are less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, according to a study led by radiation oncologists at Roswell Park Comprehensive Cancer Center.
“Polypharmacy,” or the concurrent use of multiple medications, can lead to harmful drug interactions—which is especially dangerous for cancer patients about to undergo therapy, according to a study led by Wilmot Cancer Institute researchers.
Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
The Association of Community Cancer Centers is establishing two efforts targeted at improving cancer screening, care, and mortality rates for the Appalachian region of the U.S.
Researchers at The University of Texas MD Anderson Cancer Center identified a strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6.
Effective anti-vaping advertisements geared to teens have the greatest impact when they emphasize the adverse consequences and harms of vaping e-cigarettes, use negative imagery, and avoid memes, hashtags and other “teen-centric” communication styles, according to a study by researchers at UNC Lineberger Comprehensive Cancer Center.
The phase III SKYSCRAPER-01 did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
Initial results from the ANTLER phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) demonstrated a 100% overall response rate and 80% complete response rate in cohort 1 (n=5 evaluable).
